Public Citizen Agrees With AMA On (Drug) Liability, Petitions FDA On Generic Labeling
This article was originally published in The Pink Sheet Daily
The consumer watchdog group asks that ANDA holders be able to file a supplemental label change through the changes-being-effected procedure.
You may also be interested in...
In Pliva v. Mensing, the high court said it was impossible for generic manufacturers to comply with both state tort laws and FDA regulations requiring them to have the same labels as those for brand name counterparts.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.